2015. OA was confirmed by semen analysis and normal spermatogenesis at testis needle biopsy in all patients. The operation method for VE anastomosis was two-stitch longitudinal intussusception technique. Patients who had prior vasectomy or history of vas deferens trauma/injury were excluded. The age, hormone profile, semen parameters, obstruction level, semen quality at proximal vas deferens cutting end and patency rates were analyzed.
INTRODUCTION AND OBJECTIVES: Spinal cord injury (SCI) occurs most often to young men. Infertility is a major sequela of SCI. Anejaculation and abnormal semen parameters are seen in 90% of the cases. Currently there is no established standard of care for the management of infertility in these men, largely due to a lack of education of healthcare providers at all levels. Consequently, couples with SCI male partners are often over-treated with expensive and unnecessary procedures. A 3 year educational program funded by the Craig Neilsen Foundation has been developed to train practitioners in methods and techniques for managing infertility in this population.
METHODS: A teaching curriculum was developed based on our 27 years of experience in the management of infertility in men with SCI. The training is performed at our center or at outside centers if requested and is comprised of the following items:
1) The core of the curriculum is a half day of lectures and videos 2) Two half-days of hands-on training on the techniques of penile vibratory stimulation (PVS) and electroejaculation (EEJ) as well as management of autonomic dysreflexia and retrograde ejaculation. This is part of the training curriculum at our site and can be performed at other sites if the users so wish. 3) A syllabus, copy of the PowerPoint presentation and instructional videos will be supplied to trainees which may be used to teach future healthcare providers of all types. 4) The program offers Continuing Medical Education (CME) credits (7.5 hours for the full course) for physicians. 5) Limited travel reimbursement is available for professionals who train at our center in Miami.
RESULTS: During our first year (December 2015 -December 2016), educational materials (syllabus and comprehensive 30 minute instructional video) were developed. The program was presented at the Academy of Spinal Cord Injury Professionals (ASCIP) 2016 meeting and has been selected as an instructional course for the 2017 annual AUA meeting. A total of 9 physicians from the USA, Canada, Spain, Brazil and Israel have been trained to date at our center. Multiple requests for training have been received and are scheduled for future dates.
CONCLUSIONS: This educational program addresses a gap in knowledge among health care professionals on the topic of management of infertility in men with SCI. We encourage interested professionals to take advantage of this training opportunity, which will be available through December 2018.
Source of Funding: Craig H. Neilsen Foundation Grant #365254
PD68-07 POLICY ON POSTHUMOUS SPERM RETRIEVAL: SURVEY OF 75 MAJOR ACADEMIC MEDICAL CENTERS Nicholas Waler*, Ranjith Ramasamy, Miami, FL INTRODUCTION AND OBJECTIVES: Very few studies have addressed attitudes on posthumous sperm retrieval due to the ethical and legal ramifications of the use of gametes after death. We evaluated the presence and content of a policy on posthumous sperm retrieval at the 75 major academic medical centers in the U.S.
METHODS: We surveyed the 75 major academic medical centers as ranked for research in 2016 by U.S. News & World Report using a questionnaire based telephone/web survey. We gathered data on presence and content of posthumous sperm retrieval policies. If not published, we contacted the legal counsel for the medical center, the ethics and compliance offices, the Urology Department, as well as the infertility center for each institution, in that order.
RESULTS: Out of the 75 major academic medical centers, we gathered data on posthumous sperm retrieval from 25 (33.3%). Of the 25 institutions, nine (36%) had policies regarding posthumous sperm retrieval, fifteen (60%) did not have a policy, and one center remained undisclosed. Five of the fifteen medical centers without policies have discussed development of a policy but did not formalize it due to lack of legal guidance as a barrier to policy adoption. Out of the nine centers that had a policy, four required prior written consent, while five allowed for verbal or inferred consent from the surviving life partner.
CONCLUSIONS: Very few, about 1/3, of the surveyed academic medical centers have policies on posthumous sperm retrieval. Medical centers can adopt individualized policies based on guidelines published by the American Society for Reproductive Medicine. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1341
Source 
INTRODUCTION AND OBJECTIVES:
We aim to determine the effect of anastrazole on hormonal and seminal parameters in hypoandrogenic subfertile men. We also aim to assess whether seminal parameter changes are correlated to the magnitude of increase in testosterone to estrogen ratio in men responding to treatment.
METHODS: A retrospective review was performed of all hypogonadal subfertile men attending a male infertility clinic and treated with anastrazole. Hormone analysis before treatment, 2 weeks after starting treatment and 4 months after were performed. Hormone analysis included measurements of total testosterone, estradiol, sex-hormone binding globulin, albumin, FSH and LH, and bioavailable testosterone was calculated. Semen analyses before treatment and 4 months after treatment were recorded. Total motile sperm count was calculated from the semen analysis. For statistical analysis, variables are presented as median interquartile range or mean AE standard error. A matched pairs analysis estimated significance of change in laboratory values and semen analyses with treatment. A sub-group analysis was performed of men with baseline oligozoospermia. In this group, we used linear regression to identify correlations between changes in hormone concentrations and increase in semen parameters.
RESULTS: The study group consisted of 86 subfertile hypoandrogenic men with low testosterone to estradiol ratio (n¼78) or a prior aversive reaction to clomiphene citrate (n¼8). 95.3% of patients had an increased serum testosterone and decreased serum estradiol following treatment with anastrozole. Sperm concentration and total motile counts improved in 18 out of 21 subfertile hypoandrogenic oligozoospermic men treated with anastrozole. In these men, the magnitude of total motile count increase was significantly correlated with the change in the testosterone to estradiol ratio. None of the men with azoospermia or cryptozoospermia experienced an improvement in sperm in the ejaculate and microTESE recovery rates were 72.7% in these men.
CONCLUSIONS: Approximately 95% of men with hypoandrogenism responded with improved endocrine parameters, and a subset of oligozoospermic men (approximately 25% of all patients) displayed significantly improved sperm parameters. In that subset, increase in sperm parameters was correlated with the change in the testosterone to estradiol ratio, which argues for a physiological effect of treatment. There are currently no oral treatments of male infertility approved for use by the Food and Drug Administration. The selective estrogen receptor modulator Clomiphene is the most commonly prescribed such agent, however its usage is only described in case series. We sought to characterize the demographics and usage patterns of Clomiphene for male infertility across the United States.
Source of Funding: None
METHODS: This is a retrospective cohort study of individuals in the Truven Health MarketScanâ claims database from 2001 to 2009. This US database provides information of insurance claims filed for the care of privately insured individuals with employment-based insurance. While the number of enrollees varies between years, recent years contained up to 30 million people. Pharmacy claims were used to identify the usage patterns of Clomiphene among male enrollees. Associated diagnoses and treatments were identified by utilizing International Classification of Diseases, 9th edition (ICD-9) and Current Procedural Terminology (CPT) codes. Rates of side effects previously reported for Clomiphene were compared 6 months before and 6 months after medication usage.
RESULTS: 3,922 men took Clomiphene and represented the primary study cohort, with a mean age of 35 years. Usage varied between 0.3% to 0.8%, with the highest prevalence among men 30-39 years old. No trend of usage was noted during the study period. Associated diagnoses of Clomiphene users included male infertility (59%), testicular hypofunction (32%), erectile dysfunction (8.6%), and low libido (0.6%). Infertility evaluation with semen analysis was performed in 55% of men. Testing for testosterone, LH, and FSH was done in 38%, 31%, and 35%. The median time of use was 2.4 months, with 73% of men stopping within 6 months, 17% stopping within the first year, and 3% continuing for more than 2 years. No increased risk of reported Clomiphene side effects (thrombotic events, vision problems, gynecomastia, mental disorders, liver disease, nausea, or skin problems) were apparent in men taking the medication.
CONCLUSIONS: The current report is the first to characterize the demographics and national usage patterns of Clomiphene, the most commonly prescribed oral agent for male infertility. Knowledge of adjuvant testing and prescribing practices for Clomiphene may inform and improve patient care. No increased risk of reported side effects was detected. Additional studies are needed to further understand indications, efficacy, and safety of Clomiphene use in men. 

INTRODUCTION AND OBJECTIVES:
Multiple studies have demonstrated a higher intrauterine insemination (IUI) pregnancy success in men with >4% normal morphology compared to men with 4% normal sperm morphology; other studies have not demonstrated this relationship. We performed a systematic review and meta-analysis to assess the effect of abnormal sperm morphology on pregnancy success for couples undergoing IUI.
METHODS: We performed a systematic search of MEDLINE, EMBASE, and Clinicaltrial.gov for studies evaluating semen
